Jan 15 2021 Read 639 Times
A license agreement with two Netherlands Institutes enabling development of a novel clinical laboratory test for minimal residual disease (MRD) status directly on serum samples of multiple myeloma patients has been announced by French company Sebia.
The partnership with Erasmus University Medical Center in Rotterdam and the Radboud University Medical Center in Nijmegen, aims to offer a more accessible and sensitive MRD test based on serum-protein electrophoresis (SPE), immunofixation and free light chains. These techniques are recommended by the International Myeloma Working Group (IMWG). The specific terms of the agreement have not been disclosed.
“Very high sensitivity MRD assessment in blood will revolutionise patients’ myeloma management and speed up therapeutic innovations. This unique personalised targeted mass spectrometry technology brings unprecedented clinical value in fighting myeloma,” said Pierre Sonigo, chief scientific officer at Se